Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Update

Liminatus Pharma Inc. (NASDAQ:LIMN) was the target of a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 2,404,454 shares, a growth of 106.0% from the June 30th total of 1,167,107 shares. Based on an average daily volume of 75,297,149 shares, the days-to-cover ratio is currently 0.0 days. Approximately 5.9% of the shares of the company are sold short.

Liminatus Pharma Trading Down 3.5%

Shares of LIMN stock opened at $0.10 on Friday. The stock has a market cap of $5.17 million, a P/E ratio of -0.23 and a beta of 5.62. Liminatus Pharma has a 1 year low of $0.10 and a 1 year high of $6.84. The stock has a 50 day simple moving average of $0.13 and a 200 day simple moving average of $0.30.

Liminatus Pharma (NASDAQ:LIMN) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.03) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Liminatus Pharma in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Liminatus Pharma has a consensus rating of “Sell”.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.